Literature DB >> 20460803

alpha-Glucosidase inhibition properties of cucurbitane-type triterpene glycosides from the fruits of Momordica charantia.

Nguyen Xuan Nhiem1, Phan Van Kiem, Chau Van Minh, Ninh Khac Ban, Nguyen Xuan Cuong, Nguyen Huu Tung, Le Minh Ha, Do Thi Ha, Bui Huu Tai, Tran Hong Quang, Tran Minh Ngoc, Young-In Kwon, Hae-Dong Jang, Young Ho Kim.   

Abstract

Fourteen cucurbitane-type triterpene glycosides (1-14) were isolated from a methanol extract of Momordica charantia fruits, including three new compounds, charantosides A-C (1, 5, 6). Their structures were elucidated by chemical and spectroscopic methods. All isolated compounds were evaluated for alpha-glucosidase inhibitory effect. Of which, 12 and 13 showed moderate inhibitory activity against alpha-glucosidase. Whereas, 2, 3, 6-11, and 14 showed weak inhibitory activity, and 1, 4, and 5 were inactive.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20460803     DOI： 10.1248/cpb.58.720

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN： 0009-2363            Impact factor:   1.645


  13 in total

Review 1.  Bitter melon: a panacea for inflammation and cancer.

Authors:  Prasad R Dandawate; Dharmalingam Subramaniam; Subhash B Padhye; Shrikant Anant
Journal:  Chin J Nat Med       Date:  2016-02

2.  Inhibition of nuclear transcription factor-κB and activation of peroxisome proliferator-activated receptors in HepG2 cells by cucurbitane-type triterpene glycosides from Momordica charantia.

Authors:  Nguyen Xuan Nhiem; Pham Hai Yen; Nguyen Thi Thanh Ngan; Tran Hong Quang; Phan Van Kiem; Chau Van Minh; Bui Huu Tai; Nguyen Xuan Cuong; Seok Bean Song; Young Ho Kim
Journal:  J Med Food       Date:  2012-01-16       Impact factor: 2.786

Review 3.  Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

Authors:  Komal Raina; Dileep Kumar; Rajesh Agarwal
Journal:  Semin Cancer Biol       Date:  2016-07-21       Impact factor: 15.707

4.  Wild bitter gourd improves metabolic syndrome: a preliminary dietary supplementation trial.

Authors:  Chung-Huang Tsai; Emily Chin-Fun Chen; Hsin-Sheng Tsay; Ching-jang Huang
Journal:  Nutr J       Date:  2012-01-13       Impact factor: 3.271

Review 5.  Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs.

Authors:  Angelica Artasensi; Alessandro Pedretti; Giulio Vistoli; Laura Fumagalli
Journal:  Molecules       Date:  2020-04-23       Impact factor: 4.411

Review 6.  The Effect of Momordica charantia in the Treatment of Diabetes Mellitus: A Review.

Authors:  Zhuo Liu; Jing Gong; Wenya Huang; Fuer Lu; Hui Dong
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-16       Impact factor: 2.629

Review 7.  Overview of Botanical Status in EU, USA, and Thailand.

Authors:  Weena Jiratchariyakul; Gail B Mahady
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-21       Impact factor: 2.629

8.  Biotransformation of Momordica charantia fresh juice by Lactobacillus plantarum BET003 and its putative anti-diabetic potential.

Authors:  Farhaneen Afzal Mazlan; M Suffian M Annuar; Yusrizam Sharifuddin
Journal:  PeerJ       Date:  2015-10-29       Impact factor: 2.984

9.  In vitro and in vivo α-amylase and α-glucosidase inhibiting activities of the protein extracts from two varieties of bitter gourd (Momordica charantia L.).

Authors:  Sundar Poovitha; Madasamy Parani
Journal:  BMC Complement Altern Med       Date:  2016-07-18       Impact factor: 3.659

10.  Five New Pregnane Glycosides from Gymnema sylvestre and Their α-Glucosidase and α-Amylase Inhibitory Activities.

Authors:  Phan Van Kiem; Duong Thi Hai Yen; Nguyen Van Hung; Nguyen Xuan Nhiem; Bui Huu Tai; Do Thi Trang; Pham Hai Yen; Tran Minh Ngoc; Chau Van Minh; SeonJu Park; Jae Hyuk Lee; Sun Yeou Kim; Seung Hyun Kim
Journal:  Molecules       Date:  2020-05-28       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.